REG - Fevertree Drinks PLC - Total Voting Rights

Fevertree DrinksAnnouncement

04/08/2020 14:20

RNS Number : 1062V
  
Fevertree Drinks PLC
  
04 August 2020
  
 

4 August 2020
 
Fevertree Drinks plc
 ("Fever-Tree" or the "Company")
 
Total Voting Rights
 
The Company's total issued share capital consists of 116,261,263 ordinary shares of 0.25p each ("Ordinary Shares") with one voting right per Ordinary Share. The Company does not hold any Ordinary Shares in Treasury.
Therefore, the total number of voting rights in the Company is 116,261,263. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
 
Ends
 
For further information:
 
Investor queries
Ann Hyams, Director of Investor Relations I ann.hyams@fever-tree.com I +44 (0)7435 828 138
 
Nominated Advisor and Joint Broker - Numis Securities
Garry Levin I Matt Lewis I Hugo Rubinstein I +44 (0)20 7260 1000
 
Joint Broker - Investec Bank plc
David Flin I Alex Wright I David Anderson I +44 (0)20 7597 5970
 
Media queries
Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024
 
Brunswick Group I fevertree@brunswickgroup.com I +44 (0) 207 404 5959
 
Notes to Editors:
Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 70 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade").
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
TVREAAPLEDLEEFA